(Press-News.org) ROCHESTER, Minn. — Mayo Clinic researchers have identified a specific immune cell that can be targeted to give a boost to standard immunotherapies for cancer. Two research teams, working collaboratively but using distinct approaches, found that "first-responder" immune cells known as myeloid cells can be manipulated to enhance the activity of tumor-killing T cells.
The finding suggests that enhanced myeloid cells may boost certain immune checkpoint therapies, which are the standard of care for some cancers but may not have lasting effects. A clinical trial is now being developed at Mayo Clinic to test the enhanced cells in patients.
In a study in Journal for ImmunoTherapy of Cancer, Mayo Clinic researchers detailed how they found a way to boost cancer-killing T cells. The goal was to improve treatments that interfere with immunosuppressive proteins, PD-1 and PD-L1, which together suppress T cells' ability to fight cancer. Even though PD-L1 immunotherapies aim to block PD-L1, the researchers found that the molecule can persist through a natural recycling process that puts it back in play.
"Our study found the importance of the recycling process, and we present a way to address it," says Haidong Dong, M.D., Ph.D., a cancer immunology researcher at Mayo Clinic Comprehensive Cancer Center and principal investigator of the study.
The research team developed an antibody, H1A, which they found can reduce PD-L1 in human myeloid cells and keep it from recycling. The protein PD-L1 is present in abundance on the surface of myeloid cells. When the protein was prevented from recycling on myeloid cells, the cells then boosted the action of cancer-killing T cells.
"We now have a tool that can completely remove PD-L1 and in doing so we have more myeloid cell activation," says lead author of the study, Michelle Hsu, who conducted the research as her graduate thesis at Mayo Clinic Graduate School of Biomedical Sciences. "Identifying the myeloid cell was an unexpected discovery," she says.
Another Mayo Clinic team took a different approach and arrived at a similar conclusion about the importance of myeloid cells. A research team led by immunology researcher Jessica Lancaster, Ph.D., at Mayo Clinic in Arizona, reported in iScience that macrophages, a type of myeloid cell, play a role in activating the cancer-killing T cells.
Using the complex approach of live-cell microscopy, the team found that in mice, T cells interact closely with the macrophages and create a molecular environment that has greater capacity to kill a tumor.
"This is a paradigm shift for PD-L1 immunotherapy, which has traditionally focused on the interaction of the tumor and the T cells," says Dr. Lancaster. "We found that it’s important to co-opt the macrophage, which acts as another immune cell partner."
Further, says lead author Tina Kwok, who completed the studies during her Ph.D. research at Mayo Clinic, "We can directly reprogram tumor macrophages to be more pro-inflammatory. They can become better T-cell activators and drive better tumor control. Reprogramming of the macrophage may be key to being able to prevent therapy resistance and change outcomes for patients."
Based on the findings from both labs, a phase 1 clinical trial of H1A is being planned. The research could ultimately better address resistance to immunotherapy and expand treatment options for people with cancer.
Review the studies in Journal for ImmunoTherapy of Cancer and iScience for a complete list of authors, disclosures and funding.
###
About Mayo Clinic Comprehensive Cancer Center
Designated as a comprehensive cancer center by the National Cancer Institute, Mayo Clinic Comprehensive Cancer Center is defining the cancer center of the future, focused on delivering the world's most exceptional patient-centered cancer care for everyone. At Mayo Clinic Comprehensive Cancer Center, a culture of innovation and collaboration is driving research breakthroughs in cancer detection, prevention and treatment to change lives.
About Mayo Clinic
Mayo Clinic is a nonprofit organization committed to innovation in clinical practice, education and research, and providing compassion, expertise and answers to everyone who needs healing. Visit the Mayo Clinic News Network for additional Mayo Clinic news.
END
Mayo Clinic researchers find enhancing the body’s ‘first responder’ cells may boost immune therapy for cancer
2025-10-29
ELSE PRESS RELEASES FROM THIS DATE:
Secret to a long life? In bowhead whales, a protein repairs damaged DNA
2025-10-29
Bowhead whales—the only warm-blooded mammal that outlives humans—can survive for 200 years and seldom get age-related diseases like cancer. University of Rochester researchers discovered a new clue to the whales’ longevity: an abundant protein called CIRBP that helps repair DNA.
Acquiring cancer is a complex process that involves biology, inherited genes, and environmental exposures. Along the way, if breaks in DNA occur and the genetic damage is not repaired, cancer is more likely. The team found that in bowhead whales, the DNA-repair protein CIRBP, was present at 100-fold higher levels compared to other mammals.
Wilmot Cancer Institute ...
MIT study: Identifying kids who need help learning to read isn’t as easy as A, B, C
2025-10-29
CAMBRIDGE, MA -- In most states, schools are required to screen students as they enter kindergarten — a process that is meant to identify students who may need extra help learning to read. However, a new study by MIT researchers suggests that these screenings may not be working as intended in all schools.
The researchers’ survey of about 250 teachers found that many felt they did not receive adequate training to perform the tests, and about half reported that they were not confident that children who need extra instruction in reading end up receiving it.
When performed successfully, these screens can be essential ...
Plant biomass substance helps combat weeds
2025-10-29
A study published in the journal ACS Sustainable Chemistry and Engineering and featured on its cover showed that a fraction obtained from lignin, an organic polymer responsible for the rigidity of plant cell walls, was able to improve the performance of nanoparticles with herbicide. The study was conducted by researchers from three research institutions in the state of São Paulo, Brazil: São Paulo State University (UNESP), the State University of Campinas (UNICAMP), and the Federal University of São Carlos (UFSCar).
"Lignin has antioxidant properties and is one of the main components of plant biomass, but it's still underutilized and often ...
Veterans with epilepsy after traumatic brain injury may have higher mortality rates
2025-10-29
MINNEAPOLIS — Military veterans who develop epilepsy after a traumatic brain injury may have a higher mortality rate in the following years than veterans who develop epilepsy with no previous traumatic brain injury, according to a study published on October 29, 2025, in Neurology®, the medical journal of the American Academy of Neurology.
“While these findings need to be validated in future studies, we recommend that people who develop epilepsy after a traumatic brain injury are closely monitored, and, especially if seizures do not respond well to treatment, are prioritized for surgery or changing to new medications without delay,” said study ...
Who is more likely to lose vision due to high brain pressure?
2025-10-29
MINNEAPOLIS — If untreated, a disorder of high brain pressure called idiopathic intracranial hypertension can lead to vision loss. But this disorder can develop without noticeable symptoms, making it hard to catch. A new study looks at how these vision problems develop and proposes a way to predict who will develop issues. The study is published on October 29, 2025, in Neurology®, the medical journal of the American Academy of Neurology.
“The number of cases of idiopathic intracranial hypertension has been increasing, and it mainly affects young women, so we need more information about who is more likely to develop vision problems and how that process ...
Scripps Research professor awarded $3.2 million to advance type 1 diabetes research
2025-10-29
LA JOLLA, CA—Luc Teyton, professor in the Department of Immunology and Microbiology at Scripps Research, has received a five-year, $3.2 million grant from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) to help answer how type 1 diabetes manifests and develop potential therapeutics to reverse or prevent the disease.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks the cells that produce insulin—a critical hormone that regulates the blood sugar of the body. Approximately 1.6 million Americans live with type 1 diabetes, and while genetics play a strong role in susceptibility, ...
Anna Wuttig wins Bayer Foundation Early Excellence in Science Award
2025-10-29
CHICAGO, IL – The Bayer Foundation has named Dr. Anna Wuttig, the Neubauer Family Assistant Professor of Chemistry at the University of Chicago, as the recipient of its Early Excellence in Science Award in the Chemistry category. The award celebrates young, international researchers who are pioneering their respective fields, recognizing Dr. Wuttig for her innovative work “advancing electrocatalysis for energy storage and conversion, and medicinal chemistry.”
Dr. ...
Electric vehicles outperform gasoline cars in lifetime environmental impact
2025-10-29
After two years of use, lithium-ion battery electric vehicles (BEVs) result in a reduction in cumulative carbon dioxide (CO₂) emissions compared to fossil-based internal combustion engine (ICE) vehicles, according to a new study published this week in the open-access journal PLOS Climate by Pankaj Sadavarte of Duke University, US, and colleagues.
The transportation sector accounts for 28% of US greenhouse gas emissions in the US and growing consensus supports electric vehicle adoption to address climate and air quality challenges. However, ongoing debate surrounds whether lithium-ion batteries are truly cleaner ...
Kilimanjaro has lost 75 percent of its natural plant species over the last century
2025-10-29
A new study suggests that, between 1911 and 2022, land-use change was the primary direct cause of the loss of 75% of natural plant species on the lower slopes of Mount Kilimanjaro. Andreas Hemp of the University of Bayreuth, Germany, and colleagues present these findings in the open-access journal PLOS One on October 29, 2025.
Kilimanjaro is a dormant tropical volcano in Tanzania and Africa’s tallest mountain. Millions of people living in the area rely on Kilimanjaro’s diverse ecosystems for such benefits as timber, food, and water regulation. But the variety of species found in these ecosystems—their biodiversity—is declining ...
Spider web “decorations” may help pinpoint location of captured prey
2025-10-29
The long-standing mystery around why spider webs sometimes feature “extra touches” known as stabilimenta has been revisited in a new study which suggests that their wave-propagation effects could help spiders locate captured prey. Gabriele Greco of the Swedish University of Agricultural Sciences and colleagues present these findings in the open-access journal PLOS One on October 29, 2025.
Many spider species build spiral wheel-shaped webs—orb webs—to capture flying prey, and many can incorporate stabilimenta into the web structure. These “decorations” may ...